Rocket Pharmaceuticals (RCKT) EBIT (2016 - 2025)
Historic EBIT for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.2 million.
- Rocket Pharmaceuticals' EBIT rose 2474.22% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 851.46%. This contributed to the annual value of -$273.2 million for FY2024, which is 521.68% down from last year.
- Per Rocket Pharmaceuticals' latest filing, its EBIT stood at -$52.2 million for Q3 2025, which was up 2474.22% from -$71.1 million recorded in Q2 2025.
- Over the past 5 years, Rocket Pharmaceuticals' EBIT peaked at -$34.0 million during Q2 2021, and registered a low of -$73.7 million during Q2 2024.
- Over the past 5 years, Rocket Pharmaceuticals' median EBIT value was -$62.7 million (recorded in 2024), while the average stood at -$58.5 million.
- The largest annual percentage gain for Rocket Pharmaceuticals' EBIT in the last 5 years was 2516.0% (2021), contrasted with its biggest fall of 8127.58% (2021).
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' EBIT stood at -$44.3 million in 2021, then crashed by 55.83% to -$69.1 million in 2022, then grew by 8.4% to -$63.3 million in 2023, then grew by 0.92% to -$62.7 million in 2024, then grew by 16.66% to -$52.2 million in 2025.
- Its EBIT was -$52.2 million in Q3 2025, compared to -$71.1 million in Q2 2025 and -$64.4 million in Q1 2025.